Eisai Press Release


Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 20, 2024 08:35 JST
Eisai Co., Ltd. announced today that it has been selected for "Human Capital Leaders 2023" and "Human Capital Management Gold Quality" in the "Human Capital Survey 2023" jointly conducted by HR Technology Consortium, HR Research Institute (ProFuture Inc.) and MS&AD InterRisk Research & Consulting, Inc.
More info..

Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
Feb 16, 2024 08:31 JST
Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate).
More info..

Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
Feb 01, 2024 17:04 JST
Eisai Co., Ltd. announced today that fully-fledged operations have begun at Eisai Pharmaceuticals Africa (Pty) Ltd, a pharmaceutical sales subsidiary recently established in Johannesburg, South Africa, and direct sales operations and business activities have commenced in Africa.
More info..

Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis
Jan 26, 2024 15:26 JST
Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices Agency (PDMA) in Japan.
More info..

Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan
Jan 18, 2024 14:12 JST
Eisai Co., Ltd. announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible.
More info..

Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time
Jan 17, 2024 16:08 JST
Eisai Co., Ltd. announced today that it has been listed in the 2024 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc.
More info..

Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024
Jan 16, 2024 09:25 JST
Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and virtually.
More info..

Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU
Jan 11, 2024 15:33 JST
Eisai Co., Ltd. announced today that the Scientific Advisory Group (SAG) will convene to discuss the marketing authorization application (MAA) of lecanemab (generic name, brand name: LEQEMBI), which is currently under review by the European Medicines Agency (EMA).
More info..

Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China

Jan 10, 2024 09:15 JST
Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab-irmb) has been approved in China as a treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia.
More info..

Development of Prediction Model for Brain Amyloid-Beta Accumulation Using Wristband Sensor
Dec 29, 2023 13:30 JST
Oita University and Eisai Co., Ltd. (Eisai) hereby announce the development of the world's first machine learning model to predict amyloid beta (Abeta) accumulation in the brain using a wristband sensor.
More info..

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tasurgratinib for Biliary Tract Cancer with Fgfr2 Gene Fusion
Dec 19, 2023 16:24 JST
Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for its in-house discovered fibroblast growth factor (FGF) receptor (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor tasurgratinib succinate (generic name, development code: E7090, ?tasurgratinib?) for biliary tract cancer with FGFR2 gene fusion.
More info..

Eisai and Mizuho Sign Sustainability-Linked Loan Agreement
Dec 14, 2023 17:02 JST
Eisai Co., Ltd. and Mizuho Bank, Ltd. announced today that the companies have signed a sustainability-linked syndicated loan agreement, which comes into effect today.
More info..

"LEQEMBI Intravenous Infusion" (Lecanemab) for the Treatment of Alzheimer's Disease to be Launched in Japan on December 20
Dec 14, 2023 15:39 JST
Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI Intravenous Infusion" (200 mg, 500mg, lecanemab) will be launched in Japan on December 20, following its scheduled inclusion in the price listing on the Japan National Health Insurance (NHI) Drug Price List.
More info..

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
Dec 11, 2023 09:28 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) today announced that the Phase 3 LEAP-001 trial evaluating LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai.
More info..

Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand
Nov 30, 2023 15:25 JST
Eisai Co., Ltd. announced today that its Thai sales subsidiary Eisai (Thailand) Marketing Co., Ltd., (Eisai Thailand) has made an agreement to collaborate with the Department of Medical Services (DMS), Ministry of Public Health (MOPH) of Thailand to further enhance the access to treatments for dementia including Alzheimer's disease (AD) in Thailand.
More info..

Eisai to Present Latest Data on Perampanel at The 77th American Epilepsy Society (AES) Annual Meeting
Nov 22, 2023 08:28 JST
Eisai Co., Ltd. announced today that the company will have a total of nine poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa) at the 77th American Epilepsy Society Annual Meeting (AES 2023), to be held in Orland, Florida and virtually from December 1-5, 2023.
More info..

LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023
Nov 20, 2023 16:05 JST
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) was awarded both the Best New Drug and Clinical Advance of the Year for the Phase III Clarity AD study at the Scrip Awards 2023, held by Citeline.
More info..

LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023
Oct 25, 2023 19:43 JST
Eisai Co. Ltd. announced today that TIME has selected Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) as one of THE BEST INVENTIONS of 2023 in the Medical Care category.
More info..

Eisai to Present New Data from LEQEMBI (Lecanemab-Irmb) Phase 3 Clarity Ad Study and Other Alzheimer's Disease Pipeline Research at The Clinical Trials on Alzheimer's Disease (CTAD) Conference
Oct 16, 2023 13:07 JST
Eisai Co. Ltd announced today that the company will present new data from the phase 3 Clarity AD study for its Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use and new data on the subcutaneous formulation in development at the 16th annual Clinical Trials on Alzheimer's Disease (CTAD) conference.
More info..

Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023
Oct 11, 2023 12:07 JST
Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2023, which is taking place virtually and in-person in Madrid, Spain from October 20 to 24.
More info..

Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc.
Oct 04, 2023 18:08 JST
Eisai Co., Ltd. hereby announcesthat the Company has today decided to absorb and merge with KAN Research Institute, Inc., the Company's wholly owned subsidiary on April 1, 2024.
More info..

Eisai Launches New "Innovation" Page on Corporate Website
Sep 28, 2023 16:05 JST
Eisai Co., Ltd. announced today that it has launched a new "Innovation" page on its corporate website.
More info..

Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance"
Sep 28, 2023 13:49 JST
Tokio Marine & Nichido Fire Insurance Co., Ltd. and Eisai Co., Ltd. announced that they have co-developed "Dementia Care Support Insurance" to financially support early detection and early treatment for dementia as a part of their business alliance for the realization of a Dementia Inclusive Society.
More info..

"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan
Sep 25, 2023 14:17 JST
Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" Intravenous Infusion (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD).
More info..

Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer's Day, September 21
Sep 21, 2023 11:26 JST
Eisai Co., Ltd. announced today on World Alzheimer's Day, that it has released a dementia awareness video, "Life Goes On 2023: Two Memories, One Story", on its dementia information website "Sodan.e-65" and YouTube, which are intended to deepen the understanding of dementia.
More info..

Eisai Establishes Theoria Technologies Co., Ltd., A New Digital Business Company To Build A Dementia Ecosystem
Sep 12, 2023 18:05 JST
Eisai Co., Ltd. announced today that it has established a digital business company Theoria technologies Co., Ltd. ("Theoria technologies") which will accelerate the development of a dementia ecosystem. Theoria technologies is a wholly owned subsidiary of Eisai.
More info..

Eisai Listed for 22nd Consectutive Year In FTSE4Good Index Series, An Index for Socially Responsible Investment
Aug 04, 2023 12:04 JST
Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 22nd consecutive year since its initial inclusion in 2002.
More info..

Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
Jul 20, 2023 10:23 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb (generic name, U.S. brand name: LEQEMBI) treatment showed reductions in amyloid-beta (Abeta) pathology and downstream biomarker changes.
More info..

Eisai to Present the Latest Alzheimer's Disease Pipeline and Research
Jul 12, 2023 09:05 JST
Eisai Co. Ltd announced today that the company will present the latest findings on its Alzheimer's disease (AD) pipeline and research, including Eisai's anti-amyloid beta (Abeta) protofibril* antibody for the treatment of Alzheimer's disease (AD).
More info..

Latest Release


More Latest Release >>